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original work is propObjective: To identify predictors of faster time to virological suppression among infants
starting combination antiretroviral therapy (cART) early in infancy.
Design: Cohort study of infants from Europe and Thailand included in studies partici-
pating in the European Pregnancy and Paediatric HIV Cohort Collaboration.
Methods: Infants with perinatal HIV starting cART aged less than 6 months with at least
1 viral load measurement within 15 months of cART initiation were included. Multi-
variable interval-censored flexible parametric proportional hazards models were used
to assess predictors of faster virological suppression, with timing of suppression
assumed to lie in the interval between last viral load at least 400 and first viral load
less than 400 copies/ml.
Results: Of 420 infants, 59%were female and 56% from Central/Western Europe, 26%
United Kingdom/Ireland, 15% Eastern Europe and 3% Thailand; 46 and 54% started a
boosted protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-
based regimen, respectively. At cART initiation, the median age, CD4þ% and viral
load were 2.9 [interquartile range (IQR): 1.4–4.1] months, 34 (IQR: 24–45)% and 5.5
(IQR: 4.5–6.0) log10 copies/ml, respectively. Overall, an estimated 89% (95% confi-
dence interval: 86–92%) achieved virological suppression within 12 months of cART
start. In multivariable analysis, younger age [adjusted hazard ratio (aHR): 0.84 per
month older; P<0.001], higher CD4þ% (aHR: 1.11 per 10% higher; P¼0.010) and
lower log10 viral load (aHR: 0.85 per log10 higher; P<0.001) at cART initiation
independently predicted faster virological suppression.
Conclusion: We observed a significant independent effect of age at cART initiation,
even within a narrow 6 months window from birth. These findings support the
earliest feasible cART initiation in infants and suggest that early therapy influences
key virological and immunological parameters that could have important conse-
quences for long-term health.
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The clinical benefits of starting combination antiretroviral
therapy (cART) early in HIV-infected infants have been
demonstrated in several observational studies and trials.
The Children with HIV Early Antiretroviral Therapy
(CHER) trial showed that starting cART before 12 weeks
of age markedly reduces mortality and morbidity in HIV-
infected infants [1,2].Thesefindingswere confirmed in the
European Infant Collaboration (EIC) observational study
[3] and the French perinatal cohort [4]. Several other
studies have shown that early cART initiation controls
proviral replication [5], limits establishment of latent HIV
reservoirs [6–8], preserves immune function [9] and
contributes to long-term viral suppression [10,11]. Rare
case reports have further highlighted the beneficial effect of
early cART in sustaining HIV remission in children who
subsequently discontinue cART [12–15].
Several studies investigating virological outcomes have also
demonstrated that early cART improves initial viral control
in infants, although results have beenvariable. For instance,
an Italian study reported that infants starting cART at less
than 6 months of age had better virological responses
compared with those starting after 6 months of age over all
follow-up time-points [16]. A subgroup analysis of data
from the EIC cohort showed that early therapy within 3
months of life was associated with a faster control of viral
replication [11]. Similarly, a trial evaluating safety and
tolerability of three cART regimens in the United States
and Puerto Rico showed that early therapy in the first 3
months of life was associated with improved long-term
viral suppression [17]. However, in contrast, a recent South
African study reported inconsistent benefits of early cART
on timing of virological suppression in infants starting
cART less than 6 months of age [18]. In addition, few
studies have examined factors associated with time to
virological suppression in infants starting cART before 6
months of age; most studies have evaluated children
initiating cART during the first year of life [19–21] or at
older ages [22] and results have been variable.
Therefore, the aim of our study was to investigate
predictors of faster virological suppression, focusing on
infants with perinatal HIV initiating standard cART
within the first 6 months of life living in Europe and
Thailand and included in studies participating in the
European Pregnancy and Paediatric HIV Cohort
Collaboration (EPPICC).Methods
Study inclusion criteria
Data from the EPPICC Paediatric merger 2014
(n¼ 3953) were used, as described previously [23,24].
In brief, the EPPICC merged individual patient data onroutine demographic, clinical, laboratory and treatment-
related variables from 19 observational cohorts across 17
countries prepared according to a standardised data
specification. The inclusion criteria for this analysis were
infants with perinatal HIVand aged less than 6 months at
start of standard cART, defined as boosted protease
inhibitor (bPI) or nonnucleoside reverse transcriptase
inhibitor (NNRTI) and two or more NRTIs, with a
baseline viral load measure at cART initiation and at least
one viral load within the 15 months following initiation.
Statistical analysis
The endpoint for this analysis was virological suppression.
The exact time of viral suppression could not be observed
and it was only known to have occurred at some point in
an interval of time. Therefore, interval-censored methods
for analysing survival data were required to accurately
estimate the distribution of time of the event (i.e.
virological suppression). Owing to the nature of our
observational cohort study, there were natural differences
in follow-up visit schedules across regions resulting in
subsequent differences in gap between consecutive viral
load measurements by region. As a result, interval-
censored methods were also required to estimate an
unbiased effect of region. In our main analysis, the time of
virological suppression was assumed to have occurred in
the interval between last viral load at least 400 and first
viral load less than 400 copies/ml [referred as ‘virological
suppression (Interval)’ thereafter]. Time from cART
initiation to virological suppression was analysed using
time-to-event methods, censoring follow-up at the
earliest of last viral load measurement before more than
15-month gap in measurements or last viral load
measurement. The cumulative probability of infants
achieving virological suppression over time from cART
initiation was estimated using interval-censored flexible
parametric survival models. In sensitivity analyses,
cumulative probabilities were also estimated using
Kaplan–Meier methods and nonparametric maximum
likelihood estimate (MLE) for interval-censored data, as
implemented in the R package interval (R Core Team
(2017). R: A language and environment ßor statistical
computing. R Foundation for Statistical U¨omputing,
Vienna, Austria. URLhttps://www.R-project.org/) [25].
Univariable and multivariable interval-censored flexible
parametric proportional hazards survival models were
used to identify predictors of faster virological suppres-
sion. These models were chosen as the main analysis to
allow for analysis of interval censored data, where
virological suppression was assumed to occur in the
interval between last viral load at least 400 and first viral
load less than 400 copies/ml. These models further
extend standard parametric models using restricted cubic
splines rather than linear functions for the underlying log
cumulative hazard, as implemented in Stata stpm function
[26]. Akaike information criteria (AIC) was used to
identify the best-fitting model (lowest AIC), testing 1–6
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cumulative hazard. Predictors identified from univariable
models with P less than 0.10 met criteria for inclusion
into multivariable model, along with those identified a
priori (geographical region and initial cART regimen).
Backward stepwise elimination (exit probability P¼ 0.05)
was applied to reach the final multivariable model. The
functional form of significant predictors was explored
using regression splines.
We evaluated the following factors: age at cART initiation,
baseline viral load, CD4þ% and cell count, sex, ethnicity,
initial cART regimen (bPI or NNRTI and two or more
NRTI), infant antiretroviral prevention of mother-to-
child transmission (PMTCT) prophylaxis regimen given
within 4 weeks of birth, maternal antiretroviral PMTCT
regimen used in the prenatal and delivery period, birth
abroad (whether infants were born in the same country in
which they were enrolled for HIV care), year of birth, year
of cART initiation, Centers for Disease Control and
Prevention (CDC) C event by cART initiation and
geographical region. Geographical region of cohort was
categorised a priori, as described previously [24]: Eastern
Europe (Russia andUkraine), Central andWesternEurope
(Belgium, Germany, Italy, Netherlands, Poland, Portugal,
Romania, Spain, Sweden, Switzerland, France and
Greece), United Kingdom/Ireland and Thailand. Missing
values for baseline viral load (18%) andCD4þ% (22%)were
multiply imputed by chained equations (20 cycles), on the
complete EPPICC dataset to avoid imputation bias.
Imputation diagnostics was performed by adjusting
number of imputations to minimize proportion of total
sampling variance that is due to missing data.
Sensitivity analyses were carried out using both multiply
imputed and nonimputed data (complete case analysis)
and by considering two additional definitions of time of
virological suppression: first, Midpoint between last viral
load at least 400 and first viral load less than 400 copies/ml
[referred as ‘virological suppression (Midpoint)’]; second,
date viral load less than 400 copies/ml [referred as
‘virological suppression (Observed)’]. The proportional
hazards assumption for each predictor was tested and
accounted for by including predictor time (_t) interac-
tion term in the multivariable model, where applicable.
To further confirm results, Cox proportional hazards
models and interval-censored parametric survival models
with Weibull distribution were also fitted. Stata version
15.1 (Stata Corporation, College Station, Texas, USA)
was used for all analyses, unless otherwise stated.Results
Patient characteristics
Of the 3953 children included in the dataset, 420 (11%)
infants met the study inclusion criteria of beingperinatally HIV-infected, aged less than 6 months at
cART initiation with at least 1 viral load measurement
within 15months of cART start (1998–2013) (Fig. 1). Of
these, 59% were female, 35% were white and 29%were of
black ethnicity (Table 1). Most (90%) were born in the
same country in which they were enrolled for HIV care
and the vast majority (94%) were born after the year 2000.
In total, 56% were from Central/Western Europe, 26%
from United Kingdom/Ireland, 15% from Eastern
Europe and 3% from Thailand. Among infants that
had PMTCT prophylaxis data available, over half (59%)
received PMTCT and 44% received maternal PMTCT,
and 16% had a CDC C event by the time of
cART initiation.
Median age at cART initiation was 2.9 (interquartile
range: 1.4–4.1) months, with 43% initiating cART after
the year 2008. Forty-six percent of infants started on a bPI
(lopinavir) based regimen, and 54% on a NNRTI
(nevirapine) based regimen. Median CD4þ%, CD4þ cell
count and viral load at cART initiation were 34 (24–
45)%, 1781 (995–2644) cells/ml and 5.5 (4.5–6.0) log10
copies/ml, respectively (Table 1). Of the 420 infants
included, 17 (4%) had one viral load after cART start. The
remaining 403 (96%) had at least two viral loads. The
median and mean number of viral load measurements
after cART start was 15 and 19 per infant, respectively.
Median duration of follow-up after cART initiation was
5.2 (2.1–8.8) years. Median gap between consecutive
viral load measurements was 9 (5–13) weeks and this
varied by geographical region, ranging from 7 weeks in
the United Kingdom/Ireland, 9 weeks in Central/
Western Europe, 17 weeks in Thailand to 18 weeks in
Eastern Europe. Baseline viral load was missing in 76
infants (18%). These missing values were multiply
imputed for analysis. The numbers missing baseline viral
load by age at cART start bracket were similar. The
proportions missing versus nonmissing baseline viral load
were also not significantly different by age bracket
(P¼ 0.795) (Supplementary Appendix 1, http://
links.lww.com/QAD/B452).
Cumulative probability of virological suppression
Overall, the cumulative probability of achieving virolog-
ical suppression (Interval) by 12 months after cART
initiation was estimated at 89% [95% confidence interval
(CI): 86–92]%, using the interval-censored flexible
parametric survival model (Supplementary Fig. 1,
http://links.lww.com/QAD/B452). In sensitivity analy-
ses, the cumulative probabilities estimated by the
nonparametric MLE method were very similar to those
obtained using the parametric survival model. The
probabilities of virological suppression (Midpoint) and
(Observed) by 12 months were estimated (Kaplan–
Meier) at 84% (80–87)% and 77% (73–81)%, respectively
(Supplementary Fig. 1, http://links.lww.com/QAD/
B452).
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(Complete EPPICC Paediatric merger 
2014 dataset) 
3442 (Aged ≥6 months at cART start) 
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11 (Did not have any VL data) 
12 (No VL data aer cART start) 
Excluded 
511 
Excluded 
39 (No VL data in the ﬁrst 15 months of cART start) 
Excluded 
29 (Started on non-standard cART regimens) 
488 
449 
420 
(Perinatally HIV-infected; aged <6 months at cART start; had ≥1 VL 
measure in the ﬁrst 15 months of cART start; started on standard 
cART regimen [bPI or NNRTI plus ≥2 NRTI]) 
Fig. 1. Patient inclusion flow chart. This figure shows patient inclusion selection from the complete European Pregnancy and
Paediatric HIV Cohort Collaboration Paediatric merger 2014 dataset.Baseline predictors of virological suppression
Results of interval-censored univariable and multivari-
able analyses using multiply imputed data are shown in
Table 2. In multivariable analysis, independent predictors
of faster virological suppression (Interval) were younger
age at cART initiation [adjusted hazard ratio (aHR): 0.84
(95%CI: 0.78–0.91) per month older; P< 0.001], higher
baseline CD4þ% [aHR: 1.11 (95% CI: 1.03–1.20) per
10% higher; P¼ 0.010] and lower baseline log10 viral load
[aHR: 0.85 (95% CI: 0.78–0.93) per log10 higher;
P< 0.001], adjusting for initial cART regimen and
geographical region. Figure 2 illustrates the significant
effect of age at cART initiation on time to virological
suppression. Of note, in univariable analysis, higher
CD4þ cell count also predicted faster virological
suppression. However, due to multicollinearity with
CD4þ%, CD4þ cell count was not included in the final
multivariable model. CD4þ% was included as it is a more
stable measurement in children aged less than 5 years
[21,27]. There was no significant effect of any of the
remaining factors examined on time to virological
suppression (Table 2).Sensitivity analyses of predictors of virological
suppression
Restricted to the complete case analysis, the same factors
(age at cART initiation, baseline CD4þ% and viral load)
remained significantly associated with faster virological
suppression (Interval) (Supplementary Table 1, http://
links.lww.com/QAD/B452). Regression spline analysis
further revealed a linear relationship of significant
predictors with the outcome (Supplementary Fig. 2,
http://links.lww.com/QAD/B452). Results from mul-
tivariable analyses of time to virological suppression
(Midpoint) and (Observed) were similar, both with and
without multiple imputation (Supplementary Tables 1
and 2, http://links.lww.com/QAD/B452). In some
sensitivity analyses, initial cART regimen and/or geo-
graphical region were found to violate the proportional
hazards assumption (i.e. interact with analysis time)
hence, corresponding interaction terms were included in
the relevant final multivariable models to account for this
effect. Additional univariable and multivariable analyses
using Cox proportional hazards models and interval-
censored parametric survival models with Weibull
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Table 1. Baseline characteristics.
N¼420 Median (IQR) or N (%)
Sociodemographic characteristics, Na
Sex
Male 173 (41%)
Female 247 (59%)
Ethnicityb
White 146 (35%)
Black 121 (29%)
Other 19 (5%)
Unknown 134 (32%)
Geographical region
UK/Ireland 109 (26%)
Thailand 14 (3%)
Eastern Europe 61 (15%)
Central and Western Europe 236 (56%)
Birth abroad, N¼415
No 374 (90%)
Yes 41 (10%)
Year of birth
<2000 24 (6%)
2000 396 (94%)
HIV-related parameters
Baseline
CD4þ%, N¼329 34 (24–45)
CD4þ (cells/ml), N¼340 1781 (995–2644)
Viral load (copies/ml), N¼344 314116 (34324–1000000)
Log10 viral load (copies/ml), N¼344 5.5 (4.5–6.0)
CDC C event by cART initiation
No 353 (84%)
Yes 67 (16%)
ART-related characteristics
Age at cART initiation (months) 2.9 (1.4–4.1)
Year of cART initiation
1998–<2004 105 (25%)
2004–<2008 133 (32%)
2008 182 (43%)
Initial cART regimen
bPIþ2 NRTI 194 (46%)
NNRTIþ2 NRTI 150 (36%)
NNRTIþ3 NRTI 76 (18%)
Maternal PMTCTc, N¼326
No 181 (56%)
Yes 145 (44%)
If yes, the most potent PMTCT regimen used in the prenatal and delivery period, N¼145
PMTCT given but regimen unknown 10 (7%)
Mono or dual therapy including an NNRTI 20 (14%)
Triple therapy including an NNRTI 15 (10%)
Triple therapy not including an NNRTI 70 (48%)
Other 30 (21%)
Infant PMTCTd, N¼332
No 135 (41%)
Yes 197 (59%)
If yes, the most potent PMTCT regimen given within 4 weeks of birth, N¼197
PMTCT given but regimen unknown 15 (7.6%)
Mono or dual therapy including an NNRTI 56 (28%)
Triple therapy including an NNRTI 41 (21%)
Triple therapy not including an NNRTI 7 (3.6%)
Other 78 (40%)
bPI, boosted protease inhibitor – lopinavir (LPV); cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR,
interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitors; nucleoside reverse transcriptase inhibitors; PMTCT, prevention of
mother-to-child transmission; VL, viral load.
aNumbers shown if data were available in less than 420 infants.
bEthnicity listed as a separate category if more than 20 per category, otherwise these are combined into the ‘Other’ category.
cMaternal PMTCT regimen used in the prenatal and delivery period.
dInfant PMTCT regimen given within 4 weeks of birth.
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Table 2. Univariable and multivariable predictors of virological suppression (Interval).
Univariable model Multivariable modelM
Predictors HR (95% CI) P value aHR (95% CI) P value
At cART initiation
Age (per month older) 0.83 (0.77–0.88) <0.001 0.84 (0.78–0.91) <0.001
CD4þ% (per 10% higher) 1.16 (1.08–1.24) <0.001 1.11 (1.03–1.20) 0.010
CD4þ cell count (per 500 cell higher) 1.13 (1.07–1.18) <0.001 – – –
Viral load (per log10 higher) 0.80 (0.74–0.87) <0.001 0.85 (0.78–0.93) <0.001
Sex (Ref: male)
Female 1.03 (0.83–1.27) 0.810
Infant PMTCT (Ref: no)
Yes 1.16 (0.91–1.47) 0.221
Maternal PMTCT (Ref: no)
Yes 1.19 (0.94–1.51) 0.145
Birth abroad (Ref: no)
Yes 0.99 (0.70–1.40) 0.968
Year of birth (Ref: <2000)
2000 1.44 (0.93–2.24) 0.106 – – –
CDC C event by cART initiation (Ref: no)
Yes 0.81 (0.61–1.08) 0.151
Year of cART initiation (Ref: 1998–<2004)
2004–<2008 0.95 (0.73–1.24) 0.695 – – –
2008 1.27 (0.98–1.65) 0.073 – – –
Initial cART regimena (Ref: bPIþNRTI)
NNRTIþ2 NRTI 0.95 (0.75–1.21) 0.696 0.83 (0.64–1.07) 0.156
NNRTIþ3 NRTI 1.04 (0.78–1.39) 0.780 0.93 (0.63–1.39) 0.740
Ethnicity (Ref: Black)
White 0.86 (0.66–1.11) 0.246
Other 1.11 (0.66–1.87) 0.700
Unknown 0.94 (0.72–1.22) 0.645
Geographical regiona (Ref: Central/Western Europe)
UK/Ireland 1.08 (0.85–1.37) 0.540 1.29 (0.93–1.80) 0.131
Thailand 0.97 (0.54–1.75) 0.921 1.77 (0.92–3.39) 0.085
Eastern Europe 0.88 (0.64–1.21) 0.434 1.13 (0.79–1.62) 0.505
In bold, P less than 0.05; bPI, boosted protease inhibitor – lopinavir (LPV); CDC, Centers for Disease Control and Prevention; NRTI, nucleoside
reverse transcriptase inhibitors; NNRTI, nonnucleoside reverse transcriptase inhibitor – nevirapine (NVP); baseline VL was defined as closest
measurement within 6 months before and 1 week after cART initiation and was expressed in copies/ml; baseline CD4þ% and cell count were
defined as closest measurements within 6 months before and 1 month after cART initiation. In all cases, the closest pre-cART measurement was
taken, if available. Note: In univariable analysis, higher CD4þ cell count also predicted faster virological suppression. However, due to
multicollinearity with CD4þ%, CD4þ cell count was not included in the final multivariable model. CD4þ% was included as it is a more stable
measurement in children aged less than 5 years than CD4þ cell count [21,27]. 95%CI, 95% confidence interval; aHR, hazard ratio adjusted for the
other factors included the multivariable model; cART, combination antiretroviral therapy; HR, hazard ratio; PMTCT, prevention of mother-to-child
transmission.
MCriteria for inclusion into the multivariable model: univariable model P less than 0.10, along with those identified a prioria (geographical region
and initial cART regimen).distribution further confirmed the main findings (data not
shown).Discussion
To our knowledge, this is the largest study reported to
date exploring predictors of faster virological response
in infants with perinatal HIV initiating cART within
6 months of life. Most infants achieved virological
suppression within 12 months of starting cART. This is
the first study to show that even amongst infants initiating
therapy within 6 months of life, earlier cART initiation
predicted faster virological suppression. Higher baseline
CD4þ% and lower log10 viral load were also independent
predictors of faster virological suppression.Our findings are consistent with the general conclusions
from smaller studies that have identified early treatment as
a determinant of faster virological suppression. The
European EIC study reported faster suppression in infants
starting cARTearlier (<3 months of age) compared with
later treated infants [11]. In another study (n¼ 128)
investigating older ART naı¨ve African children aged 1.7–
13.5 years, children younger than 8 years had increased
probability of attaining virological suppression compared
with older children [28]. Other studies conducted in the
United States/Puerto Rico (n¼ 52), Italy (n¼ 133) and
South Africa (n¼ 1748; total of five cohorts), revealed
that early therapy was a significant predictor of long-term
viral suppression in children starting cART at less than
3 months (versus 3 months of age) [17] and less than
6 months (versus 6 months of age) [16,18]. Although
determining the onset of infection in adults is
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Fig. 2. Effect of age at combination antiretroviral therapy initiation on time to virological suppression (Interval). This figure
shows the estimated cumulative probabilities of achieving virological suppression (Interval) by age at combination antiretroviral
therapy initiation during the first 12 months of antiretroviral therapy. Probabilities were estimated from the flexible parametric
survival model using multiply imputed data. Curves were averaged over 20 multiply imputed datasets.problematic, recent studies specifically designed to
capture this information, have also identified early
ART during primary infection as a key factor for faster
viral suppression in adults [29].
The estimated cumulative probability of achieving
virological suppression (Interval), (Midpoint) and
(Observed) was 89, 84 and 77%, respectively. This is
consistent with previous findings despite the variability in
definitions of suppression. In the CHER trial (n¼ 377)
conducted in South Africa, the proportion of infants with
viral load less than 400 copies/ml by 12months post-cART
initiation was 77% [30]. Similar findings were reported by
the EIC study among 139 infants starting cART before 3
months of age [11]. In two studies conducted in Kenya
(n¼ 121) and Mozambique (n¼ 119), the proportion of
children suppressed to less than 1000 copies/ml was 75%
[31] and 77% [32], respectively, by 12 months after cART
start. Similarly, in aUgandan study (n¼ 91), the probability
of suppression to less than 400 copies/ml was 83.1% in
infants starting cART less than 12 months of age [33].
Further evidence that with early intervention high levels of
suppression can be achieved comes from a pilot trial of
infants randomised to receive immediate or deferred four-
drug (three-class) antiretroviral therapy (n¼ 63) [19] at a
median age of 28 days (intrauterine-infected) and 55 days
(intrapartum-infected). The proportions attaining viro-
logical suppression to less than 400 copies/ml and less than
50 copies/ml were higher at 100% and 94%, respectively,
12 months post-cART.
The reasons for the critical timing of cART initiation on
virological suppression are unclear. The relationship withlower baseline viral load has been observed before in
various settings and at different ages [17,19,21,22,34].
There are sound virological and immunological reasons
why an individual with lower levels of circulating virus
would suppress more rapidly. The viral decay following
initiation of ART occurs in phases. Firstly, the initial
decline signifies early loss of short-lived virally productive
cells. This is followed by the slower loss of longer lived but
productive cells. Finally, there is the much slower loss of
latently infected cells [35]. In the context of our findings,
the implication would be that earlier treatment may target
the short-lived cells, which could have important
implications for limiting viral reservoirs. This in turn
may also provide optimal opportunities for adjunctive
therapies as part of the cure agenda [36].
As well as baseline viral load, faster virological suppression
was also associated with a higher baseline CD4þ% (also
CD4þ cell count). This association has been seen in
multiple studies [19,20,34] in infants, children, pregnant
women and adults. Although it is tempting to link the
lower viral load with the higher CD4þ%, they were
actually independent predictors of viral suppression,
indicating an immunological basis for this finding. Our
previous work has shown how critical early treatment is
for preserving CD4þ cell counts [37]. In the CHER
study, even though early treatment arrested CD4þ
decline, it did not fully restore levels to those seen in
HIV-uninfected children [37]. When therapy was
stopped as part of planned treatment interruption,
there was a rapid decline in CD4þ T-cells, which on
retreatment returned to levels observed before interrup-
tion. This indicates that baseline CD4þ levels provides
1162 AIDS 2019, Vol 33 No 7insight into CD4þ cell homeostasis, with individuals with
higher CD4þ having a greater proportion of recent
thymic emigrants, which are relatively resistant to HIV
infection [37]. The combination of early treatment, low
viral load and high baseline CD4þ cells is therefore
desirable for many reasons including faster immune
reconstitution [31], limiting viral reservoir seeding,
preserving age appropriate CD4þ cell homeostasis and
providing opportunities for ‘HIV cure’ [38]. Infants with
these characteristics may represent the target population
in which to investigate therapeutic vaccines, with the
ultimate goal of achieving ART-free HIV remission.
Therapeutic vaccines are an integral part of the HIV cure
agenda and an increasing global health priority [38].
Apart from age at cART initiation, baseline CD4þ% and
viral load, none of the remaining factors examined
predicted faster virological suppression in our final
multivariable analysis. A few other studies in Europe
have, however, reported significant associations with
initial cARTregimen [21] and calendar year [22] in older
children starting cART less than 18 years of age. On the
other hand, in an Ugandan study, none of the baseline
factors investigated (age, sex, CD4þ%, WHO stage,
cART regimen, weight-for-age or height-for-age z-
scores) were found to predict virological suppression to
viral load less than 400 copies/ml [33]. Although there
was no significant effect of infant and maternal PMTCT
prophylaxis on time to virological suppression, the
potential effect of PMTCT on suppression has recently
been demonstrated [39].
Our study had limitations. It was a subgroup analysis of
pooled observational cohort data, hence potential effects
of selection bias and unmeasured confounders cannot be
ruled out. Data on exact timing of HIV infection and
antiviral treatment adherence were not available and
could not be investigated. Although year of cART
initiation was not associated with time to virological
suppression, our data date back to 1998. Given the
changes in treatment guidelines over time across
countries, all analyses were adjusted for initial cART
regimen and geographical region despite their lack of
association with the outcome. Longitudinal investiga-
tion of long-term viral suppression in early treated
infants is also of interest, but was outside the scope of this
article. Finally, although our study supports the earliest
feasible cART initiation in infants, there are still
challenges that need to be addressed before infants
can indeed benefit from very early therapy. These
challenges relate to difficulties in scaling up birth testing
in low and middle income countries with the highest
burden [40–42].
In conclusion, we showed that effective treatment
response was achieved in the majority of infants
initiating cARTwithin 6 months of life across Europe
and Thailand. We identified the conditions needed toattain faster virological suppression in these infants. We
demonstrated that even amongst early treated infants,
earlier cART initiation, higher baseline CD4þ% and
lower baseline viral load independently predicted faster
virological suppression. These results provide additional
support for earlier cART initiation in infants with
perinatal HIV and indicate that early treatment
influences key virological and immunological param-
eters that could have important consequences for long-
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